ClariVest Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

ClariVest Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-84,966	Closed	-$899K	–	787
2022 Q4	$899K	Buy	+84,966	New	+$686K	0.04%	292
2020 Q4	–	Sell	-26,200	Closed	-$336K	–	838
2020 Q3	$336K	Sell	26,200 -1,600	-6%	-$20.2K	0.01%	407
2020 Q2	$393K	Buy	+27,800	New	+$351K	0.01%	441

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

ClariVest Asset Management's PRVB Position: Q1 2023 in Review

ClariVest Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 84,966 shares — an estimated $899K sold.

ClariVest Asset Management first reported a position in PRVB in Q2 2020 and held it in 3 quarters. The position peaked at $899K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

ClariVest Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
ClariVest Asset Management sold 84,966 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $899K.
ClariVest Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
ClariVest Asset Management's Provention Bio, Inc. Common Stock position peaked at $899K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on ClariVest Asset Management's 13F filing for Q1 2023, filed 8 May 2023.